B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

NCOA1

MOLECULAR TARGET

nuclear receptor coactivator 1

UniProt: Q15788NCBI Gene: 864814 compounds

NCOA1 (nuclear receptor coactivator 1) is targeted by 14 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting NCOA1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Methylene Blue1.614
2Anisomycin1.102
3Digitoxigenin 3 beta,14-Dihydroxy-5 beta-card-20(22)enolide.1.102
4Digoxin1.102
5Strophanthidin 3 beta,5,14-Trihydroxy-19-oxo-5 beta-card-20(22)-enolide.1.102
6Tubercidin1.102
7Methotrexate0.691
8Azacitidine0.691
9Azacitidine0.691
10cycloheximide0.691
11Famotidine0.691
12Lanatosides Glycosides from DIGITALIS lanata leaf. Lanatoside C has actions similar to DIGOXIN. Mixtures of lanatosides A, B, and C have also been used. (From Martindale,0.691
13Trifluridine0.691
14urolithin b0.691

About NCOA1 as a Drug Target

NCOA1 (nuclear receptor coactivator 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 14 compounds with documented NCOA1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

NCOA1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.